Hidradenitis Suppurativa in Children Treated with Finasteride—A Case Series

Mota, Fernando; Machado, Susana; Selores, Manuela

doi:10.1111/pde.13216

Cited by 27 publications

(29 citation statements)

References 12 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although patients with HS do not seem to have increased levels of androgens, beneficial clinical responses have been reported with antiandrogens, such as cyproterone acetate, spironolactone and the 5α‐reductase inhibitor finasteride . Peroxisome proliferator‐activated receptor‐γ (PPARγ) regulates adaptive immunity through Th17 differentiation and Treg functions .…”

Section: Therapeutic Agents Affect the T Helper 17 Cell/regulatory T‐mentioning

confidence: 99%

T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Therapeutic Agents Affect the T Helper 17 Cell/regulatory T‐mentioning

confidence: 99%

T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A report showed no new HS lesions 3 months following finasteride treatment, while another showed faster healing lesions (3 weeks vs. 6 months) and ultimately no new lesions after 3 years . Case series of girls with HS (6–11 years old) treated with finasteride (1–5 mg/day) for 24 months had overall improvement of disease, with a reduction in frequency and intensity of flares …”

Section: Resultsmentioning

confidence: 96%

“…A couple case series examined finasteride (5 mg/day) for hidradenitis suppurativa (HS) therapy . Five women and two men with HS unresponsive to antibiotics were treated with finasteride.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and use of finasteride in women: a systematic review

Chapman

Mesinkovska

2019

Int J Dermatology

View full text Add to dashboard Cite

Background Physicians are beginning to use finasteride as treatment for hair loss, hirsutism, and various other dermatologic conditions in women. However, the reported efficacy and use of finasteride in the female population varies widely. The purpose of this study is therefore to better define the efficacy and use of finasteride in women and identify research gaps that require further investigation. Methods A systematic review of the current literature describing finasteride use in women. Results A total of 2,683 patients participated in 65 studies involving finasteride use in women published between January 1997 and July 2017. Most randomized controlled trials (RCTs) evaluated finasteride use in women with hirsutism (48.7%) or female pattern hair loss (34.7%). RCTs recommend finasteride treatment for women with hirsutism or polycystic ovarian syndrome. Meanwhile, other forms of hair loss were studied such as alopecia, lichen planopilaris, and frontal fibrosing alopecia, but no RCTs evaluating finasteride therapy were identified. Other prospective and retrospective studies report that finasteride may improve hair loss in women with female pattern hair loss or frontal fibrosing alopecia. Overall, doses of oral finasteride ranged from 0.5 to 5 mg/day, in females aged 6–88, over a duration of 6–12 months (57.6%), as monotherapy (88.9%), and for continuous use (96.4%). Conclusion The studies reviewed highlight the finasteride dosage, length of treatment, and candidate conditions that can benefit from finasteride therapy. Future long‐term studies are necessary to fully assess the therapeutic mechanisms and potential consequences of finasteride use and to optimize treatment protocols.

show abstract

“…Randhawa et al 109 used finasteride as adjunctive therapy with significant improvement in a 7 years-old child and two 15 years-old adolescents, all female, 2 of them with concomitant endocrine disorders. Recently, Mota et al, 110 reported five cases of children with HS Hurley I (4 girls and 1 boy, diagnosed between the ages of 6 and 11 years) treated with oral finasteride as monotherapy (increasing dose up to 5 mg/day) with overall improvement and no adverse effects, but 2 patients relapsed after stopping treatment.…”

Section: -Antiandrogenic Therapymentioning

confidence: 99%

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Silva

Azevedo

Lisboa

2018

SPDV

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is as a chronic, inflammatory and recurrent skin disease of the hair follicle. Prevalence of HS is a matter of debate, with estimate rates as low as 0.00033% and as high as 4.1%. HS prevalence appears significantly higher in women and has a mean age of onset in the early 20s. The primary histopathologic event seems to be a follicular hyperkeratosis with plugging, dilatation and rupture of the hair follicle resulting with subsequent inflammation and formation of abscesses and sinus tracts. The cause of this is likely multifactorial, involving genetic factors, cigarette smoking, mechanical stress, obesity, immune aberrant response and hormonal abnormalities. HS, as a chronic inflammatory dermatosis, is associated with a variety of concomitant and secondary diseases such as metabolic syndrome, inflammatory and rheumatologic diseases, depression and malignancy, and, for this reason HS management often requires a multidisciplinary team.

show abstract

Hidradenitis Suppurativa in Children Treated with Finasteride—A Case Series

Cited by 27 publications

References 12 publications

T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities

T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities

The efficacy and use of finasteride in women: a systematic review

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Contact Info

Product

Resources

About